Mylotarg (Wyeth)
Mylotarg (Wyeth) Brand names, Mylotarg (Wyeth) Analogs
Mylotarg (Wyeth) Brand Names Mixture
- No information avaliable
Mylotarg (Wyeth) Chemical_Formula
No information avaliable
Mylotarg (Wyeth) RX_link
http://www.rxlist.com/cgi/generic2/gemtuzumab.htm
Mylotarg (Wyeth) fda sheet
Mylotarg (Wyeth) msds (material safety sheet)
Mylotarg (Wyeth) Synthesis Reference
(Sequence listed in CO MS, Avdalovic NM, Caron PC, Avdalovic MV, Scheinberg DA, Queen C: Chimeric and humanized antibodies with specificity for the CD33 antigen. J Immunol 148:1149, 1991) (Caron PC, Schwartz MA, Co MS, Queen C, Finn RD, Graham MC, Divgi CR, Larson SM, Scheinberg DA. Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia. Cancer. 1994 Feb 1;73(3 Suppl):1049-56)
Mylotarg (Wyeth) Molecular Weight
No information avaliable
Mylotarg (Wyeth) Melting Point
61 oC (FAB fragment), 71 oC (whole mAb)-Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000).
Mylotarg (Wyeth) H2O Solubility
No information avaliable
Mylotarg (Wyeth) State
Liquid
Mylotarg (Wyeth) LogP
No information avaliable
Mylotarg (Wyeth) Dosage Forms
Solution (IV Infusion)
Mylotarg (Wyeth) Indication
For treatment of acute myeloid leukemia
Mylotarg (Wyeth) Pharmacology
Used for the treatment of acute myeloid leukemia (AML), mylotarg binds to the CD33 antigen, which is expressed on the surface of leukemic cells in more than 80% of patients with AML. The CD33 antigen is not expressed on pluripotent hematopoietic stem cells or nonhematopoietic cells. This gives mylotarg the selectivity needed to target leukemic cells.
Mylotarg (Wyeth) Absorption
No information avaliable
Mylotarg (Wyeth) side effects and Toxicity
No information avaliable
Mylotarg (Wyeth) Patient Information
No information avaliable
Mylotarg (Wyeth) Organisms Affected
Humans and other mammals
